Renaissance Technologies (RenTech)'s VRDN Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 768,600 shares of Viridian Therapeutics, Inc. (VRDN) worth $14.12 M, representing 0.02% of the portfolio. First purchased in 2021-Q1, this medium-term investment has been held for 16 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in VRDN, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2026, adding 565,500 shares. Largest reduction occurred in Q2 2025, reducing 320,300 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Viridian Therapeutics (VRDN) Holding Value Over Time
Track share changes against reported price movement
Quarterly Viridian Therapeutics (VRDN) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +565,500 | Add 278.43% | 768,600 | $18.37 |
| Q1 2026 | +203,100 | New Buy | 203,100 | $19.56 |
| Q2 2025 | -320,300 | Sold Out | 0 | $0.00 |
| Q1 2025 | -50,900 | Reduce 13.71% | 320,300 | $13.48 |
| Q4 2024 | +311,600 | Add 522.82% | 371,200 | $19.17 |
| Q3 2024 | -188,000 | Reduce 75.93% | 59,600 | $22.75 |
| Q2 2024 | -14,100 | Reduce 5.39% | 247,600 | $13.01 |
| Q1 2024 | +248,300 | Add 1852.99% | 261,700 | $17.51 |
| Q4 2023 | -51,800 | Reduce 79.45% | 13,400 | $21.79 |
| Q3 2023 | -10,800 | Reduce 14.21% | 65,200 | $15.34 |
| Q2 2023 | +40,200 | Add 112.29% | 76,000 | $0.02 |
| Q1 2023 | +35,800 | New Buy | 35,800 | $0.03 |
| Q4 2022 | -101,600 | Sold Out | 0 | $0.00 |
| Q3 2022 | +101,600 | New Buy | 101,600 | $20.51 |
| Q2 2021 | -13,240 | Sold Out | 0 | $0.00 |
| Q1 2021 | +13,240 | New Buy | 13,240 | $16.69 |
Renaissance Technologies (RenTech)'s Viridian Therapeutics Investment FAQs
Renaissance Technologies (RenTech) first purchased Viridian Therapeutics, Inc. (VRDN) in Q1 2021, acquiring 13,240 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Viridian Therapeutics, Inc. (VRDN) for 16 quarters since Q1 2021.
Renaissance Technologies (RenTech)'s largest addition to Viridian Therapeutics, Inc. (VRDN) was in Q2 2026, adding 768,600 shares worth $14.12 M.
According to the latest 13F filing for Q2 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 768,600 shares of Viridian Therapeutics, Inc. (VRDN), valued at approximately $14.12 M.
As of the Q2 2026 filing, Viridian Therapeutics, Inc. (VRDN) represents approximately 0.02% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Viridian Therapeutics, Inc. (VRDN) was 768,600 shares, as reported at the end of Q2 2026.